Background: Despite the widespread use of Sacubitril/valsartan (Sac/Val) in patients with reduced ejection fraction (HFrEF), definite data on cardiac remodeling under treatment are still lacking. Methods and aim of the study: We conducted a retrospective analysis on a large cohort of 201 consecutive HFrEF ambulatory patients who started Sac/Val in our HF unit between Sept. 2016 and Dec. 2018 on top of optimal medical treatment. Patients with both basal and follow up (at least 3 months) echocardiographic assessment (TTE) were included. Results: A follow up TTE was performed in 100 patients (male 76%; mean age 67.4±11.1 years; medium follow-up 309±182 days). Baseline characteristics are shown in Tab.1. 34% of the patients reached the maximal dose (97/103 b.i.d.) while 18 interrupted the treatment. We observed an overall significant improvement in ejection fraction (EF), end-diastolic and end-systolic ventricular volumes (EDV/ESV), while just a trend in pulmonary pressures (PAPs) and mitral regurgitation (MR) reduction was noted (p=0.06 and 0.09 respectively). Non ischemic etiology and high dose of Sac/Val were predictors of better remodeling (Fig.1). Conclusion: Sac/Val led to an early favorable ventricular remodeling assessed by echocardiography. The benefit was greater in patients on higher Sac/Val dose and non ischemic etiology.

Early cardiac reverse remodelling in a large cohort of patients with HFrEF treated with Sacubitril/Valsartan / M. Mapelli, E. Salvioni, I. Mattavelli, V. Sassi, V. Mantegazza, V. Volpato, C. Vignati, F. De Martino, S. Paolillo, L. Fusini, M. Muratori, M. Pepi, P. Agostoni. - In: EUROPEAN HEART JOURNAL SUPPLEMENTS. - ISSN 1554-2815. - 21:Suppl. J(2019 Dec). ((Intervento presentato al 80. convegno Congresso Nazionale Società Italiana di Cardiologia (SIC) tenutosi a Roma nel 2019.

Early cardiac reverse remodelling in a large cohort of patients with HFrEF treated with Sacubitril/Valsartan

M. Mapelli
Primo
;
V. Sassi;V. Mantegazza;C. Vignati;P. Agostoni
Ultimo
2019

Abstract

Background: Despite the widespread use of Sacubitril/valsartan (Sac/Val) in patients with reduced ejection fraction (HFrEF), definite data on cardiac remodeling under treatment are still lacking. Methods and aim of the study: We conducted a retrospective analysis on a large cohort of 201 consecutive HFrEF ambulatory patients who started Sac/Val in our HF unit between Sept. 2016 and Dec. 2018 on top of optimal medical treatment. Patients with both basal and follow up (at least 3 months) echocardiographic assessment (TTE) were included. Results: A follow up TTE was performed in 100 patients (male 76%; mean age 67.4±11.1 years; medium follow-up 309±182 days). Baseline characteristics are shown in Tab.1. 34% of the patients reached the maximal dose (97/103 b.i.d.) while 18 interrupted the treatment. We observed an overall significant improvement in ejection fraction (EF), end-diastolic and end-systolic ventricular volumes (EDV/ESV), while just a trend in pulmonary pressures (PAPs) and mitral regurgitation (MR) reduction was noted (p=0.06 and 0.09 respectively). Non ischemic etiology and high dose of Sac/Val were predictors of better remodeling (Fig.1). Conclusion: Sac/Val led to an early favorable ventricular remodeling assessed by echocardiography. The benefit was greater in patients on higher Sac/Val dose and non ischemic etiology.
Settore MED/11 - Malattie dell'Apparato Cardiovascolare
Società Italiana di Cardiologia
https://academic.oup.com/eurheartjsupp/issue/21/Supplement_J
Article (author)
File in questo prodotto:
File Dimensione Formato  
Early Cardiac remodelling sacubitril valsartan

accesso aperto

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 127.42 kB
Formato Adobe PDF
127.42 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/712552
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact